
Eiger BioPharmaceuticals EIGR
Annual report 2023
added 04-08-2024
Eiger BioPharmaceuticals Shares 2011-2026 | EIGR
Annual Shares Eiger BioPharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.48 M | 1.39 M | 33.9 M | 29.9 M | 22.8 M | 13.7 M | 8.73 M | 6.01 M | 1.59 M | 1.57 M | 1.18 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.9 M | 1.18 M | 11.1 M |
Quarterly Shares Eiger BioPharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.3 M | 44.3 M | 44.1 M | - | 44 M | 43.1 M | 35.3 M | 34.6 M | 33.9 M | 33.9 M | 33.9 M | 33.9 M | 29.9 M | 25.5 M | 24.5 M | 24.5 M | 24.4 M | 23.4 M | 19.2 M | 19.2 M | 14.3 M | 12 M | 10.5 M | 10.5 M | 8.37 M | 8.37 M | 8.36 M | 8.36 M | 7.62 M | 7.07 M | 936 K | 274 K | 195 K | 194 K | 194 K | 194 K | 20.8 M | 18.5 M | 11.9 M | 884 K | 884 K | 884 K | 884 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.3 M | 194 K | 18.3 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
244 M | $ 96.98 | -6.26 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
220 M | - | - | $ 866 M | ||
|
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | ||
|
Burford Capital Limited
BUR
|
219 M | $ 5.16 | 4.56 % | $ 820 M | ||
|
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | ||
|
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | ||
|
Cerus Corporation
CERS
|
191 M | $ 2.73 | 34.49 % | $ 520 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
166 M | $ 21.96 | -2.2 % | $ 3.64 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
4.28 M | - | - | $ 269 M | ||
|
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | ||
|
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
68.9 M | - | -7.31 % | $ 87 M | ||
|
Calithera Biosciences
CALA
|
73.9 M | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
106 M | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
69.9 K | - | - | $ 3.74 B | ||
|
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - | ||
|
Cardiff Oncology
CRDF
|
66.8 M | $ 1.71 | -1.45 % | $ 114 M | ||
|
Caladrius Biosciences
CLBS
|
8.33 M | - | -16.75 % | $ 25.8 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | ||
|
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
9.27 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
85.1 M | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | ||
|
Editas Medicine
EDIT
|
88.7 M | $ 2.92 | -2.83 % | $ 259 M | ||
|
Dynavax Technologies Corporation
DVAX
|
130 M | - | - | $ 2.02 B | ||
|
Edesa Biotech
EDSA
|
3.2 M | $ 17.54 | -4.02 % | $ 56.1 M | ||
|
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 3.0 | -5.96 % | $ 4.94 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
2.17 M | - | -5.68 % | $ 8.28 M | ||
|
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | ||
|
Evogene Ltd.
EVGN
|
40.4 M | $ 0.79 | 1.66 % | $ 27.9 M | ||
|
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
18.8 M | - | 17.91 % | $ 11.1 M |